Luchtwegaandoening: astma asthma
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: (All of the following criteria) • age 18-50 yr • doctors diagnosis of asthma • patients who need inhaled corticosteroids as controller medication (step 2-4 GINA guideline) and / or montelukast inhaled corticosteroids >= 3 months in the previous year • access to the internet • written informed consent
Exclusion criteria
Exclusion criteria: • inability to understand written and oral Dutch instructions • active diseases likely to interfere with the purpose of the study, such as a terminal illness or a severe psychiatric disease • daily or alternate day oral corticosteroid therapy for at least 1 month before entering the study • patients who are primarily under treatment by a pulmonologist
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Patient level: clinical outcomes (asthma control, lung function, usage of airway treatment and presence of exacerbations); self-management related outcomes (health education impact, medication adherence and illness perceptions); asthma related quality of life and patient utilities. Professional and organizational level: adherence of professionals to implementation strategies, experience with IBSM and feasibility of IBSM in daily practice. Cost-effectiveness: medical costs and health care consumption. | — |
Primary
| Measure | Time frame |
|---|---|
| 1. the proportion of practices that participate in IBSM, 2. the proportion of referred patients that participate in IBSM and 3. asthma related quality of life in participating patients. | — |
Countries
Netherlands
Outcome results
None listed